Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CCR2 | P41597 | 5/20 | 0.53 |
| ▸ | CCR5 | P51681 | 4/20 | 0.42 |
| ▸ | CCRL2 | O00421 | 1/20 | 0.40 |
| ▸ | CACNA1B | Q00975 | 4/20 | 0.38 |
| ▸ | TRPV4 | Q9HBA0 | 1/20 | 0.36 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.35 |
| ▸ | MEN1 | O00255 | 1/20 | 0.35 |
| ▸ | NR1I2 | O75469 | 1/20 | 0.34 |
| ▸ | TP53 | P04637 | 1/20 | 0.34 |
| ▸ | MAPT | P10636 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL15849382 | 1.00 | CCR2 (0.53) | CCR2CCR5CCRL2CACNA1BTRPV4 | |
| SCHEMBL3046871 | 1.00 | CCR2 (0.53) | CCR2CCR5CCRL2CACNA1BTRPV4 | |
| SCHEMBL10230513 | 0.96 | CCR2 (0.54) | CCR2CCR5CCRL2CACNA1BTRPV4 | |
| SCHEMBL16938567 | 0.96 | CCR2 (0.54) | CCR2CCR5CCRL2CACNA1BTRPV4 | |
| SCHEMBL10232173 | 0.96 | CCR2 (0.54) | CCR2CCR5CCRL2CACNA1BTRPV4 | |
| SCHEMBL20040025 | 0.94 | CCR2 (0.52) | CCR2CCR5CCRL2CACNA1BTRPV4 | |
| SCHEMBL3075473 | 0.92 | CCR2 (0.54) | CCR2CCR5CCRL2CACNA1B | |
| SCHEMBL15849359 | 0.92 | CCR2 (0.52) | CCR2CCR5CCRL2KMT2AMEN1 | |
| SCHEMBL3075562 | 0.92 | CCR2 (0.52) | CCR2CCR5CCRL2KMT2AMEN1 | |
| SCHEMBL26007572 | 0.92 | CCR2 (0.52) | CCR2CCR5CCRL2KMT2AMEN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11731981-B2 | CCR2 receptor antagonists and uses thereof | CENTREXION THERAPEUTICS CORPORATION (US) | 2023-08-22 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11731981-B2 | CCR2 receptor antagonists and uses thereof | CCR2, CCRL2, CCR1 | CCR2 1/4885CCR5 5/4885CCRL2 2/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.